Genmab — November 2012
-
nej en yoyo går ikke 200% op
-
Der er altså mange guldkorn på ASH:The combination of lenalidomide and ofatumumab was well tolerated by most patients. The patients with indolent NHL had a high response rate of 83% and a 1-year PFS of 67% https://ash.confex.com/ash/2012/webprogram/Paper50366.html
-
det ser godt ud gentogen. Hvad var sammenligningsdata på ritux?
-
ORR på 40% på refrac og relaps
-
er pænt flot
-
what? Disclosures: Vose: Glaxo Smith Kline: Research Funding; Celgene: Research Funding. Off Label Use: Lenalidamide and Ofatumumab will be discussed for use in indolent and aggressive non-Hodgkin lymphoma.
-
off label use?
-
hvorfor står der off label use?
-
den er jo af gode grunde ikke labelled
-
skal man lægge noget i det
-
men det er jo et klinisk forsøg?
-
off label det er jo kun et begreb for de læger der udskriver. Den har jo per definition ingen label i et klinisk forsøg
-
Ingen af jer der kan bruge et sommerhus i minnesota for 300 mio. kr. ?
-
godt køkken- store gryder
-
In CLL primary cases (n=8) tested, DARA (14-43% lysis) was generally superior or at least equally effective (mean+/-SD=28,78 +/- 9,78) in inducing ADCC as compared to the anti-CD20 antibodies ofatumumab (mean+/-SD=21,35 +/- 15,71) and rituximab (mean+/-SD=29,30 +/- 15,90)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind